These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 27207836

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.
    Zhang Y, Zhang Q, Chen H, Wang C.
    Life Sci; 2018 Sep 01; 208():284-294. PubMed ID: 30009824
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H, Xie X, Wang K, Chen Q, Cai S, Liu D, Luo J, Kong J.
    Mol Cell Biochem; 2020 Dec 01; 475(1-2):63-77. PubMed ID: 32767026
    [Abstract] [Full Text] [Related]

  • 5. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway.
    Xia Y, He Z, Liu B, Wang P, Chen Y.
    Mol Med Rep; 2015 Sep 01; 12(3):4530-4537. PubMed ID: 26059239
    [Abstract] [Full Text] [Related]

  • 6. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
    Liu X, Zhou X, Chen Y, Huang Y, He J, Luo H.
    Neoplasma; 2020 Jan 01; 67(1):147-157. PubMed ID: 31686523
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S, Tu Z, Xiong J, Kang G, Zhao L, Hu W, Tan H, Tembo KM, Ding Q, Deng X, Huang J, Zhang Q.
    Oncol Rep; 2017 Feb 01; 37(2):921-928. PubMed ID: 27922681
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells.
    Gao Y, Liu Z, Zhang X, He J, Pan Y, Hao F, Xie L, Li Q, Qiu X, Wang E.
    Cancer Lett; 2013 Aug 09; 336(1):231-9. PubMed ID: 23673211
    [Abstract] [Full Text] [Related]

  • 10. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
    Liu B, Pan CF, Ma T, Wang J, Yao GL, Wei K, Chen YJ.
    Mol Med Rep; 2017 Oct 09; 16(4):4107-4112. PubMed ID: 29067469
    [Abstract] [Full Text] [Related]

  • 11. C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells.
    Xie C, Pan Y, Hao F, Gao Y, Liu Z, Zhang X, Xie L, Jiang G, Li Q, Wang E.
    APMIS; 2014 Dec 09; 122(12):1251-8. PubMed ID: 25131138
    [Abstract] [Full Text] [Related]

  • 12. Reelin Promotes Cisplatin Resistance by Induction of Epithelial-Mesenchymal Transition via p38/GSK3β/Snail Signaling in Non-Small Cell Lung Cancer.
    Li JM, Yang F, Li J, Yuan WQ, Wang H, Luo YQ.
    Med Sci Monit; 2020 Aug 07; 26():e925298. PubMed ID: 32764530
    [Abstract] [Full Text] [Related]

  • 13. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
    Ju ZS, Sun B, Bao D, Zhang XF.
    Eur Rev Med Pharmacol Sci; 2020 Sep 07; 24(18):9465-9472. PubMed ID: 33015788
    [Abstract] [Full Text] [Related]

  • 14. Long non-coding RNA SNHG1 contributes to cisplatin resistance in non-small cell lung cancer by regulating miR-140-5p/Wnt/β-catenin pathway.
    Shi SL, Zhang ZH.
    Neoplasma; 2019 Sep 07; 66(5):756-765. PubMed ID: 31288529
    [Abstract] [Full Text] [Related]

  • 15. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB, Wang SX.
    Eur Rev Med Pharmacol Sci; 2019 Feb 07; 23(3):1093-1101. PubMed ID: 30779077
    [Abstract] [Full Text] [Related]

  • 16. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
    Zhou W, Wang J, Man WY, Zhang QW, Xu WG.
    Asian Pac J Cancer Prev; 2015 Feb 07; 16(6):2425-30. PubMed ID: 25824776
    [Abstract] [Full Text] [Related]

  • 17. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J, Meng Q, Zhao Y, Chen X, Cai L.
    BMC Cancer; 2016 Jul 13; 16():470. PubMed ID: 27411790
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
    Li JH, Luo N, Zhong MZ, Xiao ZQ, Wang JX, Yao XY, Peng Y, Cao J.
    Tumour Biol; 2016 Feb 13; 37(2):2387-94. PubMed ID: 26376998
    [Abstract] [Full Text] [Related]

  • 19. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y, Dong ZY, Wang JY.
    Eur Rev Med Pharmacol Sci; 2018 Aug 13; 22(15):4879-4887. PubMed ID: 30070323
    [Abstract] [Full Text] [Related]

  • 20. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
    Sui C, Meng F, Li Y, Jiang Y.
    J Transl Med; 2015 Apr 28; 13():132. PubMed ID: 25927928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.